Lifitegrast - 97%, high purity , Integrin alpha-L/beta-2 (LFA-1) antagonist, CAS No.1025967-78-5, Integrin alpha-L/beta-2 (LFA-1) antagonist

Item Number
L171714
Grouped product items
SKUSizeAvailabilityPrice Qty
L171714-25mg
25mg
3
$97.90
L171714-100mg
100mg
3
$325.90
L171714-250mg
250mg
3
$733.90
L171714-1g
1g
3
$2,640.90

LFA-1 (lymphocyte function-associated antigen-1) antagonist

Basic Description

SynonymsEN300-20605731 | 7-hydroxy-2-methyl-3-phenoxy-chromone | CS-6264 | s3714 | A900838 | Q23044263 | N-(2-(1-benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carbonyl)-3-(methanesulfonyl)-L-phenylalanine | (2S)-2-{[2-(1-benzofuran-6-carbon
Specifications & PurityMoligand™, ≥97%
Biochemical and Physiological MechanismsLFA-1 (lymphocyte function-associated antigen-1) antagonist, used to treat ocular vascular complications. Lifitegrast\xa0 is a new type of T cell integrin antagonist designed to mimic the binding epitope of ICAM-1.
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeANTAGONIST
Mechanism of actionIntegrin alpha-L/beta-2 (LFA-1) antagonist
NoteWherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description

LFA-1 (lymphocyte function-associated antigen-1) antagonist.

AI Insight

Product Properties

ALogP4.7

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

Pubchem Sid504766848
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/504766848
IUPAC Name (2S)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-3,4-dihydro-1H-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic acid
INCHI InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1
InChi Key JFOZKMSJYSPYLN-QHCPKHFHSA-N
Canonical SMILES CS(=O)(=O)C1=CC=CC(=C1)CC(C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl
Isomeric SMILES CS(=O)(=O)C1=CC=CC(=C1)C[C@@H](C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl
PubChem CID 11965427
Molecular Weight 615.48

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

8 results found

Lot NumberCertificate TypeDateItem
L2101362Certificate of AnalysisSep 18, 2023 L171714
L2101363Certificate of AnalysisSep 18, 2023 L171714
L2101364Certificate of AnalysisSep 18, 2023 L171714
L2101366Certificate of AnalysisSep 18, 2023 L171714
I2212040Certificate of AnalysisJul 06, 2022 L171714
I2212041Certificate of AnalysisJul 06, 2022 L171714
I2212042Certificate of AnalysisJul 06, 2022 L171714
I2212046Certificate of AnalysisJul 06, 2022 L171714

Safety and Hazards(GHS)

Pictogram(s) GHS08
Signal Warning
Hazard Statements

H361:Suspected of damaging fertility or the unborn child

Precautionary Statements

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P405:Store locked up.

P501:Dispose of contents/container to ...

P203:Obtain, read and follow all safety instructions before use.

P318:if exposed or concerned, get medical advice.

Related Documents

Reviews

Customer Reviews

Citations of This Product

1. Xin Meng, Ye Wang.  (2021)  Drug Repurposing for Influenza Virus Polymerase Acidic (PA) Endonuclease Inhibitor.  MOLECULES,  26  (23): (7326).  [PMID:34885905] [10.3390/molecules26237326]

References

1. Giblin PA, Lemieux RM.  (2006)  LFA-1 as a key regulator of immune function: approaches toward the development of LFA-1-based therapeutics..  Curr Pharm Des,  12  (22): (2771-95).  [PMID:16918410] [10.1021/op500134e]
2. Lam H, Bleiden L, de Paiva CS, Farley W, Stern ME, Pflugfelder SC.  (2009)  Tear cytokine profiles in dysfunctional tear syndrome..  Am J Ophthalmol,  147  (2): (198-205. e1).  [PMID:18992869] [10.1021/op500134e]
3. Murphy CJ, Bentley E, Miller PE, McIntyre K, Leatherberry G, Dubielzig R, Giuliano E, Moore CP, Phillips TE, Smith PB et al..  (2011)  The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs..  Invest Ophthalmol Vis Sci,  52  (6): (3174-80).  [PMID:21330663] [10.1021/op500134e]
4. Kapp TG, Rechenmacher F, Sobahi TR, Kessler H.  (2013)  Integrin modulators: a patent review..  Expert Opin Ther Pat,  23  (10): (1273-95).  [PMID:24050747] [10.1021/op500134e]
5. Sheppard JD, Torkildsen GL, Lonsdale JD, D'Ambrosio Jr FA, McLaurin EB, Eiferman RA, Kennedy KS, Semba CP, OPUS-1 Study Group.  (2014)  Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study..  Ophthalmology,  121  (2): (475-83).  [PMID:24289915] [10.1021/op500134e]
6. Zhong M, Gadek TR, Bui M, Shen W, Burnier J, Barr KJ, Hanan EJ, Oslob JD, Yu CH, Zhu J et al..  (2012)  Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye..  ACS Med Chem Lett,  (3): (203-6).  [PMID:24900456] [10.1021/op500134e]
7. A-González N, Castrillo A.  (2011)  Liver X receptors as regulators of macrophage inflammatory and metabolic pathways..  Biochim Biophys Acta,  1812  (8): (982-94).  [PMID:21193033] [10.1021/op500134e]
8. Xin Meng, Ye Wang.  (2021)  Drug Repurposing for Influenza Virus Polymerase Acidic (PA) Endonuclease Inhibitor.  MOLECULES,  26  (23): (7326).  [PMID:34885905] [10.3390/molecules26237326]

Solution Calculators